This educational activity is designed to incorporate evidence-based pathophysiology, diagnosis, and/or treatment of surgical disorders into clinical practice. Speakers will utilize their personal, institutional and evidence-based experience to address patient health care conditions requiring clinical and surgical treatment. Speakers will also utilize departmental quality improvement data, M&M data, and patient safety data to improve outcomes of surgical disease and other aspects of surgical patients’ general health. Evidence-based data regarding the changing aspects/newer approaches to surgical disease will be analyzed, and critical issues related to surgery within the broader scope of American health care will be discussed.
There are varying degrees to individuals’ knowledge regarding clinical and surgical treatments. While individuals may be aware of varied treatment within the surgeons’ armamentarium it is beneficial to address the topics from an evidence-based approach. Learners should both have the knowledge base and be able to apply this knowledge into their practice.
Grand Rounds will address each of these shortcomings by utilizing nationally known experts in the field. Each week will provide diverse information pertaining to these issues.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
General Surgeons, Physician Assistants, Allied Health Care Professionals
- Identify patients who would benefit from chemoprevention of pancreatic cancer.
- Discuss the benefits and limitations of a range of agents for pancreatic cancer risk reduction.
- Identify challenges to the development of effective chemoprevention agents for pancreatic cancer.
Chair, Department of Gastrointestinal Oncology
Program Leader, GI Tumor Program
H. Lee Moffitt Cancer Center
All persons in control of content have NO relevant financial relationships to disclose.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.